Is a keratoacanthoma-like lesion, a clinical variant of squamous cell carcinoma (SCC), considered a high‑risk or low‑risk form of SCC?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 4, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Keratoacanthoma-Like SCC: Risk Classification

Keratoacanthoma-like lesions (also called keratoacanthomatous SCC) are classified as LOW-RISK variants of cutaneous squamous cell carcinoma according to the American Academy of Dermatology guidelines. 1

Risk Classification Based on Histologic Subtype

The AAD guidelines explicitly categorize keratoacanthomatous SCC as a prognostically favorable histologic subtype that should be reported in pathology specimens because this information is clinically useful for risk stratification 1. This designation places it in the low-risk category alongside other favorable variants like verrucous carcinoma 1.

Treatment Implications of Low-Risk Classification

  • Standard excision with 4-6 mm margins is recommended for low-risk primary cSCC, which would include keratoacanthoma-like lesions 1
  • Curettage and electrodessication (C&E) may be considered for low-risk cSCC in non-terminal hair-bearing locations 1
  • Less aggressive surgical approaches are appropriate compared to high-risk tumors, which require Mohs micrographic surgery 1

Important Clinical Context and Caveats

The Ongoing Controversy

There is substantial debate in dermatopathology about whether keratoacanthomas represent:

  • A benign, self-limiting tumor distinct from SCC that can spontaneously regress 2, 3, 4
  • A well-differentiated variant of SCC with low malignant potential 5, 4
  • A borderline lesion between benign and malignant 6

Despite this controversy, the clinical standard is to treat keratoacanthomas surgically because definitive differentiation from well-differentiated SCC is often impossible histologically 2, 4, 7.

Key Distinguishing Features

When keratoacanthoma features are present in an SCC, this typically indicates:

  • Lower proliferative activity with fewer dispersed Ki67+ keratinocytes compared to conventional cSCC 8
  • Less immunosuppressive tumor microenvironment with fewer regulatory T-cells and different immune cell interactions 8
  • Tendency toward regression mediated by immunologic mechanisms 4
  • No reported deaths from definitive keratoacanthomas, compared to ~1.5% mortality for cSCC 2

Clinical Pitfall to Avoid

Do not assume all crateriform lesions are keratoacanthomas. Several distinct entities can present with similar crateriform architecture 6:

  • True keratoacanthoma (hair follicle-related)
  • KA-like SCC (borderline lesion)
  • KA with malignant transformation
  • Infundibular SCC (crateriform)
  • Crateriform SCC arising from actinic keratosis
  • Crateriform Bowen's disease

The last two categories are NOT related to hair follicles or true keratoacanthoma and should not be considered low-risk based on architecture alone 6.

Pathology Reporting Requirements

When keratoacanthomatous features are identified, the pathology report should include 1:

  • Degree of cellular differentiation
  • Depth of invasion in millimeters
  • Presence of perineural or lymphovascular invasion
  • Margin status
  • Specific notation of the keratoacanthomatous subtype as a favorable prognostic feature

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.